NASDAQ:XOMA XOMA Royalty Q1 2026 Earnings Results & Report XOMA Royalty missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 12, 2026. The company reported EPS of $0.17 versus the $0.19 consensus estimate, while revenue of $12.32 million fell short of the $13.91 million estimate by $1.59 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 12, 2026TimeBefore Market OpensConference Call7:00 AM ET XOMA Royalty EPS ResultsActual EPS$0.17Consensus EPS $0.19Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersXOMA Royalty Revenue ResultsActual Revenue$12.32 millionExpected Revenue$13.91 millionBeat/MissMissed by -$1.59 millionYoY Revenue GrowthN/AConference Call ResourcesSlide DeckQuarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsQuarterly report(10-Q) XOMA Royalty Q1 2026 Earnings FAQ Did XOMA Royalty beat earnings estimates for Q1 2026? XOMA Royalty (NASDAQ:XOMA) reported earnings of $0.17 per share for Q1 2026, missing the consensus estimate of $0.19. The report was announced on Tuesday, May 12, 2026. What was XOMA Royalty's revenue for Q1 2026? XOMA Royalty reported revenue of $12.32 million for Q1 2026, against a consensus estimate of $13.91 million. XOMA Royalty Earnings HeadlinesLigand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A BuyNovember 4, 2026 | seekingalpha.comPantginis Reiterates Buy on Ligand, Citing Robust Royalty Growth Prospects and XOMA Acquisition Synergies; $358 Price Target UnchangedOctober 29, 2026 | tipranks.comTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they did. Before a single vote was counted, the IMF flagged markets as increasingly exposed to a sharp correction, Ray Dalio called conditions a classic bubble, and Peter Schiff said a downturn could hit regardless of the outcome.November 12 at 1:00 AM | USA Capital Gold (Ad)LGND: XOMA Acquisition ClosedAugust 10, 2026 | finance.yahoo.comLigand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On EarningsJuly 17, 2026 | finance.yahoo.comLigand Pharma completes transformative XOMA royalty acquisitionJuly 15, 2026 | tipranks.comSee More XOMA Royalty Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email. Email Address About XOMA RoyaltyXOMA Royalty (NASDAQ:XOMA) (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders. The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways. Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.View XOMA Royalty ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going Away Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
